Across TCGA pan-cancer cohorts, ACTBP7 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated ACTBP7 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher ACTBP7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACTBP7 expression acts as an unfavorable survival marker, although some lineages such as CESC and ESCA show a favorable association.
MESO, OV, and CESC are the cancer types where ACTBP7 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.